Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 12/20 | 0.88 |
| ▸ | LIPG | Q9Y5X9 | 12/20 | 0.88 |
| ▸ | CA1 | P00915 | 3/20 | 0.49 |
| ▸ | CA2 | P00918 | 3/20 | 0.49 |
| ▸ | CA9 | Q16790 | 3/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA3 | P07451 | 1/20 | 0.49 |
| ▸ | CA4 | P22748 | 1/20 | 0.49 |
| ▸ | CA6 | P23280 | 1/20 | 0.49 |
| ▸ | CA5A | P35218 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.49 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.49 |
| ▸ | F11 | P03951 | 2/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.44 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.44 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL792244 | 0.94 | LIPG (1.00) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL20671247 | 0.89 | LPL (0.71) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL16352626 | 0.89 | LPL (0.71) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL15481281 | 0.89 | LPL (0.71) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL368960 | 0.89 | LPL (0.71) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL23988619 | 0.89 | LPL (0.71) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL228212 | 0.88 | LPL (0.71) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL25981578 | 0.87 | LPL (0.69) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL19831187 | 0.86 | LPL (0.67) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL19831153 | 0.86 | LPL (0.67) | LPLLIPGCA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 409 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12633548-B2 | Eliminating voltage delay and stabilizing impedance by electrolyte additives in alkali metal electrochemical cells | LITRONIK BATTERIETECHNOLOGIE GMBH (DE) | 2026-05-19 | — | — | US | claimed |
| CN-118561818-A | Diaryl substituted 2, 3-indoline compound or medicinal salt thereof, preparation method and application thereof | 河南大学 | 2024-08-30 | — | — | CN | claimed |
| CN-116789518-A | 2-position phenyl substituted triarylethylene photochromic material and preparation method and application thereof | 西北工业大学 | 2023-09-22 | — | — | CN | claimed |
| US-20220263102-A1 | ELIMINATING VOLTAGE DELAY AND STABILIZING IMPEDANCE BY ELECTROLYTE ADDITIVES IN ALKALI METAL ELECTROCHEMICAL CELLS | LITRONIK BATTERIETECHNOLOGIE GMBH (DE) | 2022-08-18 | — | — | US | claimed |
| EP-3997748-A1 | ELIMINATION OF VOLTAGE DELAY AND STABILIZATION OF IMPEDANCE BY ELECTROLYTE ADDITIVES IN ALKALI METAL ELECTROCHEMICAL CELLS | LITRONIK Batterietechnologie GmbH (DE) | 2022-05-18 | — | — | EP | claimed |
| US-6559310-B2 | Reacting a halogen aromatic derivative at a coupling position with a diboron derivative in the presence of a Group VIII metal catalyst and a suitable base for covalently coupling organic compounds | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2003-05-06 | — | — | US | claimed |
| US-20020193604-A1 | Aryl borates | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2002-12-19 | — | — | US | claimed |
| EP-0986541-A4 | PROCESS FOR COVALENTLY COUPLING ORGANIC COMPOUNDS UTILIZING DIBORON DERIVATIVES | COMMW SCIENT IND RES ORG (AU) | 2002-08-14 | — | — | EP | claimed |
| US-20020032339-A1 | ARYL BORATES | BORON MOLECULAR LIMITED (AU) | 2002-03-14 | — | — | US | claimed |
| EP-0986541-A1 | PROCESS FOR COVALENTLY COUPLING ORGANIC COMPOUNDS UTILIZING DIBORON DERIVATIVES | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2000-03-22 | — | — | EP | claimed |
| WO-1998045265-A1 | PROCESS FOR COVALENTLY COUPLING ORGANIC COMPOUNDS UTILIZING DIBORON DERIVATIVES | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 1998-10-15 | — | — | WO | claimed |
| US-12633548-B2 | Eliminating voltage delay and stabilizing impedance by electrolyte additives in alkali metal electrochemical cells | LITRONIK BATTERIETECHNOLOGIE GMBH (DE) | 2026-05-19 | — | — | US | disclosed |
| CN-122036730-A | Gαq/11 protein inhibitor with purine skeleton, and preparation method and application thereof | 中山大学 | 2026-05-15 | — | — | CN | disclosed |
| WO-2026099404-A1 | SULFONYLUREA DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | QUBIT PHARMACEUTICALS (FR) | 2026-05-15 | — | — | WO | disclosed |
| EP-4741375-A1 | SULFONYLUREA DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | Qubit Pharmaceuticals (FR) | 2026-05-13 | — | — | EP | disclosed |
| EP-2272822-A1 | INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 | Renascience CO., LTD. (JP) | 2011-01-12 | — | — | EP | disclosed |
| WO-2010146176-A2 | PROCESS FOR HYDROGENATION OF HALOGENOALKENES WITHOUT DEHALOGENATION | LEK PHARMACEUTICALS D.D. (SI) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010146172-A2 | NEW SYNTHETIC ROUTE FOR THE PREPARATION OF α-AMINO BORONIC ACID DERIVATIVES VIA SUBSTITUTED ALK-1-YNES | LEK PHARMACEUTICALS D.D. (SI) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010110782-A1 | METHOD FOR MANUFACTURING A BORONIC ACID ESTER COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-09-30 | — | — | WO | disclosed |
| US-20090124620-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | RENASCIENCE CO., LTD. (JP) | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124620-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | SERPINE1, SERPINC1, SERPINB1 | LPL 296/4885LIPG 416/4885CA1 1641/4885 |
| US-20020193604-A1 | Aryl borates | BRD4, ABL1, BRD3 | LPL 4181/4885LIPG 4621/4885CA1 3882/4885 |
| US-20020032339-A1 | ARYL BORATES | TBCB, HAT1, UBE2B | LPL 4584/4885LIPG 4847/4885CA1 3496/4885 |
| US-12633548-B2 | Eliminating voltage delay and stabilizing impedance by electrolyte additives in alkali metal electrochemical cells | KCNN1, HCN4, KCNN2 | LPL 4624/4885LIPG 4122/4885CA1 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.